Luzine

Quick links to important sections

Luzine

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Luzine

Quick Facts

Property Description
Active ingredient Cyromazine (N-Cyclopropyl-1,3,5-triazine-2,4,6-triamine)
Form Wettable Powder (WP), Pour-on Solution, Premix, Granules
Pharmacological class Ectoparasiticide, Insect Growth Regulator (IGR)
Common use Control of fly larvae in livestock environments
Origin Synthetic Triazine Derivative

What Type of Ectoparasiticide is Luzine?

Luzine is a product designated for veterinary use and pest control, containing the sole active ingredient Cyromazine. This compound is classified as an Ectoparasiticide and, more specifically, recognized as an Insect Growth Regulator (IGR). Cyromazine is a triazine insecticide with specific activity against dipterous larvae. This classification highlights the product's function: it selectively disrupts the development of external insect pests rather than acting as a traditional, broad-spectrum poison on adult organisms.

Composition and Available Forms of Luzine

The composition of Luzine is based on the single active ingredient, Cyromazine (C6H10N6), formulated with inert carriers suitable for different methods of administration within livestock operations. The drug forms are varied and include powders such as Wettable Powder (WP) and Soluble Powder (SP), as well as liquid preparations like a Pour-on Solution or Cutaneous Solution. This range allows for application via environmental treatment (such as a Premix in feed) or through topical application, depending on the specific setting in poultry or dairy operations.

General Purpose: How Luzine Manages Fly Pests?

The general purpose of Luzine is the effective, long-term management of problematic fly populations, which pose significant threats to animal welfare. As an IGR, the product works by targeting the fly larvae to prevent their successful maturation and emergence into reproductive adults. Cyromazine is used as an insect larvicide to control Diptera larvae and flies on livestock. The ability to disrupt the larval stage is key, offering a means of continuous population suppression and helping to mitigate severe issues like flystrike on sheep.

What side effects are possible with Luzine?

The safety profile of Luzine (Cyromazine) is established within the framework of veterinary medicinal product regulation and is primarily focused on public health safety constraints related to food consumption, along with safety for the target animal species and the environment.

Adverse Reaction Scope and Classification

Official regulatory documents classify the occurrence of serious adverse effects in the target livestock species as generally Rare to Very Rare when the product is used strictly according to the authorized field conditions. The observed safety characteristics are generally confined to specific System-Organ Classes.

Category Regulatory Observation
Gastrointestinal / Metabolic Decreases in food consumption or reduced body weight have been noted in high-dose studies.
Dermatological / Application Site Potential for mild, transient skin irritation may occur with topical forms, such as pour-on solutions.

Official Safety Constraints

The most significant safety focus is on public health protection, which is enforced by regulatory bodies through specific limitations on use:

  • Maximum Residue Limits (MRLs): Strict adherence to government-defined MRLs for Cyromazine and its primary metabolite, melamine, in edible tissues and products (meat, milk, eggs) is mandatory.
  • Withdrawal Period: An official Withdrawal Period must be respected between the final administration of Luzine and the processing of the treated animal for human consumption. This is a time-related constraint imposed to ensure compliance with MRLs.
  • Population-Specific Restrictions: Regulatory safety notes explicitly restrict the use of certain formulations in specific populations, such as in sheep producing milk for human consumption. Furthermore, the safety profile includes limitations aimed at mitigating potential environmental risks to aquatic organisms and non-target insects. These constraints define the boundary of safe and authorized product application.

Overdose and Emergency Response

Overdose and When to Seek Help

Luzine is a veterinary tranquilizer not approved for human use. Its presence in the illicit drug supply, often combined with opioids like fentanyl, is associated with a high risk of life-threatening overdose.

Overdose Symptoms and Manifestations

An overdose involving Luzine can cause severe central nervous system depression, potentially leading to death. Key symptoms may include:

  • Respiratory Distress: Slowed, shallow, or stopped breathing (respiratory depression).
  • Cardiovascular Issues: Dangerously low blood pressure (hypotension) and a slowed heart rate (bradycardia).
  • Severe Sedation: Extreme drowsiness, unresponsiveness, or an inability to be awakened.
  • Skin Complications: Repeated use is associated with the development of severe, necrotic skin ulcers and abscesses, which can occur away from the injection site.

Emergency Response

Immediate medical attention is required for any suspected overdose. The combination of Luzine with central nervous system depressants, especially opioids, intensifies the risk. Due to the high likelihood of co-occurring opioid exposure, the following actions are critical:

  1. Call 911 immediately for emergency medical assistance.
  2. Administer naloxone (if available) to reverse any opioid effects. Naloxone does not reverse the effects of Luzine, but it should still be given as it will not cause harm and may save a life by reversing the opioid component.
  3. Provide rescue breaths if the person's breathing is severely slowed or stopped, as Luzine is known to cause significant respiratory depression. Stay with the individual until first responders arrive. The sedative effects of Luzine may continue even after naloxone is administered.

Therapeutic Uses of Luzine

Luzine (Cyromazine) is commonly used in veterinary settings for the management of external pest populations. It is generally applied in contexts marked by increased discomfort or tension caused by high pest loads.

Managing Symptoms Related to Parasitic Myiasis

Luzine is primarily used to provide supportive management against parasitic blowfly strike (Myiasis), a severe clinical condition commonly found in sheep. This application is relevant for managing the symptoms that interfere with daily comfort by addressing the causes of these intense manifestations. It provides supportive protection that may assist with reducing the potential for severe symptoms related to a full infestation. The therapeutic benefit supports the well-being and helps maintain physical stability during periods of heightened symptoms. This is applicable in contexts associated with infestations by pests such as the house fly, stable fly, and lesser house fly.

Support for Chronic Environmental Stress and Health Risk

The product is relevant for the continued management of high-density fly populations in livestock and poultry environments. It is applied across domains where additional symptomatic support is needed, helping address symptoms of chronic environmental stress and irritation across the entire herd or flock. Furthermore, Luzine is applicable within clinical settings that involve acute or disruptive symptom patterns linked to fly contamination. Its application contributes to easing the overall symptom load and supporting general well-being during symptomatic phases.

Quick Fact: Relief for Stress and Pests
Primary Use Supports management of conditions related to parasitic Myiasis.
Symptom Management Helps address symptoms of chronic environmental stress and irritation.
Target Conditions Conditions involving recurrent fly infestations and subsequent health risks.
Benefit Focus Supports functional stability and helps ease the overall symptom burden.

Eligibility and Restrictions for Use

Luzine is primarily indicated for the prevention of migraine headaches and not for the treatment of an acute migraine attack. The decision to use this medication must always be made by a healthcare provider, considering the patient’s full medical history.

Who Can and Cannot Use Luzine

Appropriate Use Contraindications (Should Not Use)
Individuals suffering from frequent migraine attacks. History of depression.
Patients diagnosed with vestibular vertigo (dizziness/balance issues). History of Parkinson's disease or other extrapyramidal disorders.

Special Considerations

Certain conditions require caution and close medical supervision when using Luzine:

  • Pregnancy and Breastfeeding: Information on safety is limited. Use should only proceed after a thorough risk/benefit assessment by a physician.
  • Liver Issues: Dose adjustment may be necessary for patients with impaired liver function.
  • Existing Psychiatric Disorders: Close monitoring is required for patients with a history of other psychiatric issues, as Luzine may affect mood.
  • Allergies: This medication is contraindicated in individuals with a known hypersensitivity to the active ingredient (Flunarizine) or any of the other ingredients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Luzine (Cyromazine), an ectoparasiticide used for the management of fly pests in livestock, is primarily characterized by the absence of known interactions with other medicinal products. This determination is explicitly stated in government-approved regulatory labeling, such as the Summary of Product Characteristics (SPC) from veterinary medicines authorities.


Summary of Regulatory Interaction Status

Interaction Type Official Regulatory Status
Contraindicated Combinations None documented
Exposure-Modifying Substances None documented
Timing Requirements None stipulated
Food, Alcohol, Herbal Products No formal interactions documented

Official Interaction Statements

Because no interactions with other substances are formally known, regulatory documents do not specify any mandatory prohibitions on co-administration or restrictions related to metabolic pathways. The product's label does not list any medicines that would be contraindicated or require specific dose adjustments due to changes in drug exposure, such as increased or decreased plasma concentrations. Consequently, there are no official requirements for separating the administration of Luzine in time from other medicinal products. This structure indicates that official data does not mandate constraints for co-use based on metabolic, transporter, or pharmacodynamic interaction mechanisms, nor does it contain constraints related to specific animal populations.

Mechanism of Action

Luzine (flunarizine) acts primarily as a selective calcium entry blocker on neuronal cell membranes, specifically targeting Voltage-Dependent L-type Calcium Channels (CaV1). This action stabilizes nerve cells against excessive electrical activity by preventing the unregulated influx of calcium ions (Ca^2+), which are essential for nerve signaling and neurotransmitter release.

This mechanism modulates neuronal hyperexcitability within the central nervous system. By restricting the flow of Ca^2+, Luzine initiates a cascade that reduces the intrinsic firing frequency of sensitive neural circuits, particularly those involved in nociception and vestibular function. The outcome is the modulation of overactive physiological signaling and a reduction in neuronal responsiveness.

Beyond its primary target, Luzine also exerts a minor secondary influence on vascular smooth muscle cells, contributing to mild vasodilation and improved tissue perfusion. Furthermore, it possesses weak antagonistic activity at Dopamine D2 receptors at higher concentrations, which introduces a secondary mechanism of dopaminergic modulation of motor pathways.

Dosage and Administration Information

How to Use Luzine: Official Administration Guidelines

Luzine (Cyromazine) is used according to two primary modes of administration: Topical application to livestock and Environmental application to breeding sites. The official use instructions define a strict protocol for both dose calculation and application methodology.


Official Routes and Forms

Administration is achieved via a 6% Cutaneous Solution (Pour-on) for direct application to animals or through Water-Soluble Granules/Powders for treating contaminated surfaces. The choice of route is determined by the target: the animal for prophylactic blowfly strike control or the manure/bedding for fly larval management.


Dosing and Scheduling

Application Type Dosing Rule Frequency Pattern
Topical (Sheep) Dose is strictly weight-based, ranging from 15 mL up to 50 mL of the 6% solution, scaled according to the animal's body mass. Reapplication is required every 8 to 10 weeks to maintain continuous protection throughout the fly season.
Environmental Applied as a dry scatter or diluted spray at a rate of approximately 0.02 lb of active Cyromazine per 200 sq. ft. Application is conditional, repeated only after treated manure is removed or when active fly larvae are visually confirmed at the site.

Procedural Instructions and Constraints

The 6% topical solution is applied undiluted along the animal’s dorsal midline, from the mid-shoulder to the rump. For environmental use, granules must be diluted for spraying or scattered dry, and the product must be directed only at active breeding materials like wet manure. It is a procedural requirement that users do not mix the topical solution with other products and prevent any contamination of feed or water troughs during environmental treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Chronic Pain Management

Clinical trials investigated outcomes reported by participants with osteoarthritis (OA) and rheumatoid arthritis (RA). These studies primarily assessed pain and physical function using standardized scales over periods typically ranging from 4 to 12 weeks.

  • OA and RA: Multiple randomized controlled trials (RCTs) assessed outcomes against placebo and other non-steroidal anti-inflammatory drugs (NSAIDs). Research investigated reported measures of joint tenderness and swelling in RA, and studies assessed measurements related to the duration of joint pain in OA.

Combination Therapy Research

Research investigated the use of the drug in combination with physical therapy and monitored reported pain levels. This research was based on the hypothesis that a multimodal approach could be associated with changes in mobility measurements.

  • Specific study protocols included monitoring changes in reported pain following the initial dose.

Safety and Tolerability Profile

Safety endpoints were monitored and recorded across various phases of clinical investigation.

  • Gastrointestinal Safety: Studies compared the incidence of gastrointestinal (GI) adverse events (e.g., ulcers, bleeds) in participants taking the drug versus those taking non-selective NSAIDs. Research focused on hypothesized differences in GI event rates compared to non-selective NSAIDs.
  • Cardiovascular Risk: Trials specifically monitored the occurrence of major adverse cardiovascular events (MACE) in participants over the duration of treatment. Study data indicated a need to monitor cardiovascular endpoints in participants with a history of cardiovascular events.
  • Long-Term Use: Research included long-term study protocols, and endpoints related to liver function monitoring were recorded.

Frequently Asked Questions (FAQ)

Common questions about Luzine (FAQ)


Q: What kind of studies were done to get Luzine approved?

A: Regulatory bodies review controlled clinical trials that assess the medication's effectiveness and safety profile before approval. These studies typically compare the drug against a placebo or other standard treatments for its specific, officially approved indications.


Q: How does Luzine affect your mood or energy levels?

A: Official information indicates that common side effects include drowsiness and fatigue. Mood changes, including low mood or depression, are also reported. Official guidelines often recommend the daily dose be taken in the evening to help manage these effects.


Q: If I get pregnant, do I need to stop taking Luzine immediately?

A: Official safety data on the use of Luzine during pregnancy is limited. The decision to start or continue the medication should be made by a healthcare provider after a thorough risk-benefit assessment.


Q: What did the long-term safety studies on Luzine show?

A: Long-term clinical studies recorded endpoints related to overall safety. This monitoring included tracking major adverse cardiovascular events and changes in liver function in participants over the duration of treatment.


Q: What kind of lab tests might a doctor need to run while I'm on Luzine?

A: Regulatory warnings and special considerations indicate that monitoring of liver function tests may be recommended by a healthcare provider. This is particularly relevant for patients who have existing liver impairment.


Q: Does Luzine carry a risk of dizziness or falling, especially for older people?

A: Dizziness is a reported side effect of the medication. Official labeling advises caution for use in older adults because the risk of severe side effects may be increased in this population.


Q: Is Luzine something you take forever, or just for a short time?

A: According to common prescribing guidelines, treatment is often provided for a specific duration, such as a six-month course, after which a break may be recommended by a physician to assess the continued need for the medication.


Q: Do you get withdrawal symptoms if you stop taking Luzine?

A: Due to the drug's long half-life, meaning it remains in the body for an extended time, a traditional, abrupt withdrawal syndrome is typically not listed in regulatory documents. The drug is eliminated slowly over time.


Q: Why does Luzine take a few weeks or months to fully work?

A: Official prescribing information states that the full preventive effect of the medication is not immediately noticeable. It may take six to twelve weeks of continuous, daily treatment before the maximum benefit is observed.


Q: Is it normal to feel a bit tired when you first start Luzine?

A: Yes, tiredness and drowsiness are commonly reported side effects, especially at the start of treatment. This initial effect is often addressed in prescribing information, which recommends taking the dose in the evening.


Q: Can Luzine cause weight gain that lasts for a long time?

A: Weight gain, often associated with an increase in appetite, is listed in regulatory summaries as a very common side effect reported in clinical practice.


Q: Is Luzine a controlled substance or addictive?

A: Official safety information reports that no habit-forming tendencies have been noted for this medication. It is not classified as a controlled substance by regulatory bodies.


Q: Is there a generic version of Luzine available?

A: Luzine is a brand name. The active ingredient is flunarizine hydrochloride, and generic versions containing flunarizine are available in many countries where the drug is licensed.


Q: Can Luzine affect your sleep pattern?

A: Yes, sleep disturbances are listed as reported side effects. These can include excessive sleepiness, medically termed somnolence, as well as difficulty falling asleep, known as insomnia.


Q: Do most people have to adjust their dose of Luzine over time?

A: Some treatment regimens may recommend two successive tablet-free days each week after a period of initial daily administration. This periodic adjustment is a strategy used to maintain the therapeutic effect.


Q: Can Luzine be taken by people who have diabetes?

A: Caution is recommended regarding its use with certain oral medications for high blood sugar. Official information states that a patient's diabetic status is relevant information for the healthcare provider.


Q: If I miss a dose of Luzine, what generally happens?

A: Official product information contains specific directions for handling a missed dose. These directions generally describe the appropriate time to take a dose if remembered and when to skip it if it is close to the next scheduled time.


Q: Can Luzine make people feel more anxious at first?

A: Anxiety is listed as a potential side effect that may occur as the body adjusts to the medication. Persistent mood changes are a matter for the prescribing healthcare provider.


Q: How long after starting Luzine do patients usually notice changes?

A: While the full, maximum effect often requires continued treatment for six to twelve weeks, official information notes that some patients may begin to notice changes in their condition earlier.


Q: Is Luzine a type of antidepressant, even if it's used for other things?

A: No, Luzine is pharmacologically classified as a selective calcium channel blocker. It is not an antidepressant, but official safety information states that a history of depression is a contraindication to its use.


Q: Can men and women expect different side effects from Luzine?

A: While many side effects are common across populations, women may report specific effects such as irregular menstrual periods or galactorrhoea (unusual breast milk production).


Q: Is the tiredness side effect from Luzine something that goes away?

A: The initial tiredness and drowsiness are often expected to decrease as the body develops tolerance to the medication. However, some official sources indicate that a return of tiredness may be experienced later in treatment.


Q: Does Luzine have a black box warning from the FDA?

A: Flunarizine, the active ingredient in Luzine, is not licensed or available for prescribing in the United States. Therefore, it does not carry a Boxed Warning from the U.S. Food and Drug Administration (FDA).


Q: Why do official documents say Luzine shouldn't be used by people with certain heart conditions?

A: Caution is advised for patients with existing heart problems. Official documents note a risk of the drug potentially worsening conditions such as slow heart rate (bradycardia) or heart failure.


Q: Can Luzine be used to treat problems other than its main approved uses?

A: The drug is officially indicated and licensed only for the prevention of migraine headaches and the treatment or prevention of vestibular vertigo. Any other uses are not officially licensed by regulatory bodies.


Q: How should I handle it if Luzine makes my stomach upset?

A: Nausea, heartburn, or general stomach discomfort are potential side effects. Official guidance suggests that persistent or bothersome effects are matters for a healthcare provider.


Q: Does the time of day I take Luzine matter for its effectiveness?

A: Official prescribing information describes the dose as typically taken once a day in the evening or at night. This specific timing is suggested to help minimize the impact of common side effects like drowsiness.


Q: Is the risk of side effects higher when first starting Luzine?

A: Side effects such as tiredness and drowsiness are most common during the initial phase of treatment. Official prescribing strategies are designed to address this initial risk.


Q: How long does Luzine stay in your system after you stop taking it?

A: The drug has a long elimination half-life, meaning it is removed from the body slowly. Its half-life ranges from approximately 4 to 19 days, and it may remain detectable in the body for several weeks after discontinuation.


Q: What is the difference between the brand name Luzine and its generic name?

A: Luzine is a brand name for the active ingredient flunarizine. The generic name of the chemical compound used in the drug is flunarizine hydrochloride.


Q: Do people with high blood pressure need to be careful with Luzine?

A: While the drug itself is generally considered to have no significant effect on blood pressure, caution is advised when it is combined with other medications that lower blood pressure. This is due to a potential risk of contributing to low blood pressure (hypotension).


Q: Is there any research on Luzine use in older adults?

A: Official labeling advises caution for its use in older adults. Safety information describes the need for careful administration strategies, which often include beginning treatment with the lowest dose due to a potentially higher risk of severe side effects.


Q: Can Luzine affect how birth control pills work?

A: Official regulatory summaries note that galactorrhoea (unusual breast milk production) has been reported in a few women taking oral contraceptives while also using this medication.


Q: Is there a minimum age requirement for taking Luzine according to regulatory bodies?

A: Regulatory bodies generally do not recommend the use of this medication in patients below 18 years of age. This is due to a lack of available safety and efficacy data for the pediatric population.

How should Luzine be stored and disposed of?

The storage and disposal of Luzine (Cyromazine) must adhere strictly to governmental regulatory labeling for veterinary pesticides.

Scope Official Regulatory Requirement
Storage Temperature Store at ambient temperatures, typically below 25 C or 30 C.
Protection Requirements Must be stored in a dry, well-ventilated place, protected from direct sunlight and freezing (for liquid forms).
Container Rules Keep in the original, tightly closed container; keep out of reach of children, food, drink, and animal feeding stuffs.
Disposal Instructions Unused product and packaging must be discarded in accordance with local and national waste disposal regulations.

Regulatory documents mandate that the product must maintain stability by being stored under dry, ambient conditions and away from excessive heat. It is explicitly required to keep the product separate from all consumables and children. Disposal must follow controlled waste procedures to ensure that the product does not contaminate watercourses or sewage systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Luzine found in:

A-Z Index: